Table 1 Histopathological characterization of PXA patients
From: DNA methylation alterations in grade II- and anaplastic pleomorphic xanthoastrocytoma
PXA patients | Diagnosis | Gender, age | ICH features | Brain localization |
|---|---|---|---|---|
BRAF V600E negative (no mutation) | ||||
CD34 positive. | ||||
PXA-1 | PXA WHO grade II | 18y., female | GFAP positive. | right frontal |
MIB-1:1% | ||||
IDH1 R132H negative (no mutation). | ||||
GFAP positive. | ||||
PXA-2 | PXA WHO grade II | 17y., female | MIB-1: 1%. | right temporal |
No tumor tissue available for BRAF/CD34 characterization | ||||
BRAF V600E positive (mutated) | ||||
CD34 focal positive | ||||
PXA-3 | PXA WHO grade II | 34y., female | GFAP. Positive. | left temporal |
MIB-1: <1%. | ||||
IDH1 R132H negative (no mutation) | ||||
BRAF V600E negative (no mutation) | ||||
CD34 positive | ||||
Mitotic index <5 mitoses/10 HPF | ||||
PXA-4 precursor of PXA-5 | PXA WHO grade II | 59y., male | Immunopositivity for GFAP, S100, MAP2, | right parietal |
vimentin and EMA | ||||
MIB-1: 5-10% | ||||
IDH1 R132H negative (no mutation) | ||||
BRAF V600E negative (no mutation) | ||||
CD34 positive | ||||
Mitotic index >5mitoses/10 HPF | ||||
PXA-5 | PXA with anaplastic features | 59y., male | Immunopositivity for GFAP, S100, MAP2, | right parietal |
vimentin and EMA | ||||
MIB-1: 10-15% | ||||
IDH1 R132H negative (no mutation) | ||||
BRAF V600 E negative (no mutation) | ||||
CD34 positive | ||||
PXA-6 | PXA with anaplastic features | 22y., male | GFAP positive | right temporal |
MIB-1: 5%. | ||||
IDH1 R132H negative (no mutation) | ||||
BRAF V600 E negative (no mutation) | ||||
CD34 positive | ||||
PXA-7 | PXA WHO grade II | 44y., female | Immunopositivity for GFAP | right temporal |
MIB-1: 1%. | ||||
IDH1 R132H negative (no mutation) | ||||
BRAF V600 E negative (no mutation) | ||||
CD34 positive | ||||
PXA-8 | PXA WHO grade II | 20y., male | Immunopositivity for GFAP. | right parieto-occipital |
MIB-1: <1%. | ||||
IDH1 R132H negative (no mutation) | ||||
BRAF V600 E negative (no mutation) | ||||
CD34 positive | ||||
PXA-9 | PXA WHO grade II | 78y., female | Immunopositivity for GFAP. | right temporo-parietal |
MIB-1: <1%. | ||||
IDH1 R132H negative (no mutation) | ||||
PXA-10 | PXA WHO grade II | 15y., female | BRAFV600E negative (no mutation) | right occipital |
CD34 positive | ||||
Immunopositivity for GFAP. | ||||
MIB-1: 1%. | ||||
PXA-11 | PXA WHO grade II | 52y., male | BRAFV600E negative (no mutation) | left occipital |
CD34 positive | ||||
Immunopositivity for GFAP. | ||||
MIB-1: < 1%. | ||||
PXA-12 | PXA WHO grade II | 17 y., male | BRAFV600E positive (mutated) | left parietal |
CD34 negative | ||||
Immunopositivity for GFAP. | ||||
MIB-1: 1%. | ||||
PXA-13 | PXA WHO grade II | 37 y., female | BRAFV600E positive (mutated) | right parietal |
CD34 focal positive | ||||
Immunopositivity for GFAP | ||||
MIB-1: < 1% | ||||